The assay results indicated that the expression of basic fibroblast growth factor (bFGF, also known as FGF2) was dramatically increased in the NASH liver, which was significantly inhibited by ASTN treatment (Figure 7A, p < 0.01). The gene discussed is ASTN1; the disease is metabolic dysfunction-associated steatohepatitis.